IFRX / InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19

InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderm more_horizontal

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatme more_horizontal

InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic w more_horizontal

The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospital more_horizontal

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patie more_horizontal

InflaRx is a clinical-stage biotech that focuses on anti-inflammation therapies. Its lead therapy is also seen as a treatment for several skin disorde more_horizontal

InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investo more_horizontal

IFRX has been beaten down much like many other biotech companies. The company has a lead drug which is being considered for EUA in the US and use in t more_horizontal